CO2018003558A2 - Método de cristalización y biodisponibilidad - Google Patents
Método de cristalización y biodisponibilidadInfo
- Publication number
- CO2018003558A2 CO2018003558A2 CONC2018/0003558A CO2018003558A CO2018003558A2 CO 2018003558 A2 CO2018003558 A2 CO 2018003558A2 CO 2018003558 A CO2018003558 A CO 2018003558A CO 2018003558 A2 CO2018003558 A2 CO 2018003558A2
- Authority
- CO
- Colombia
- Prior art keywords
- crystallization
- bioavailability method
- bioavailability
- characterization
- humans
- Prior art date
Links
- 238000002425 crystallisation Methods 0.000 title 1
- 230000008025 crystallization Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220404P | 2015-09-18 | 2015-09-18 | |
| PCT/US2016/052492 WO2017049294A1 (en) | 2015-09-18 | 2016-09-19 | Crystallization method and bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018003558A2 true CO2018003558A2 (es) | 2018-07-19 |
Family
ID=58289727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0003558A CO2018003558A2 (es) | 2015-09-18 | 2018-04-04 | Método de cristalización y biodisponibilidad |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190083407A1 (enExample) |
| EP (1) | EP3362071A4 (enExample) |
| JP (1) | JP2018527392A (enExample) |
| KR (1) | KR20180053384A (enExample) |
| CN (1) | CN108601791A (enExample) |
| AU (1) | AU2016324482A1 (enExample) |
| CA (1) | CA2997378A1 (enExample) |
| CL (1) | CL2018000705A1 (enExample) |
| CO (1) | CO2018003558A2 (enExample) |
| MX (1) | MX2018002627A (enExample) |
| PE (1) | PE20180931A1 (enExample) |
| WO (1) | WO2017049294A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2459176T3 (en) | 2009-07-31 | 2017-12-04 | Gruenenthal Gmbh | Crystallization process and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| WO2019113084A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CN118593482A (zh) | 2017-12-05 | 2024-09-06 | 赛诺维信制药公司 | 非外消旋混合物及其用途 |
| CN108440449B (zh) * | 2018-04-17 | 2021-05-07 | 中国海洋大学 | 一种氢氯噻嗪与脯氨酸的共晶及其制备方法 |
| CN108558791B (zh) * | 2018-06-08 | 2021-05-07 | 中国海洋大学 | 一种乙酰唑胺与脯氨酸的共晶及其制备方法 |
| CN108570051B (zh) * | 2018-07-20 | 2021-02-02 | 中国科学院上海药物研究所 | 呋塞米-氨苯蝶啶盐、晶型i及其制备方法和应用 |
| CN108794418A (zh) * | 2018-09-18 | 2018-11-13 | 中国药科大学 | 一种缬沙坦烟酰胺共无定形物 |
| CN109568284B (zh) * | 2018-12-29 | 2020-04-24 | 广东中润药物研发有限公司 | 一种替诺福韦艾拉酚胺肠溶片及其制备方法 |
| CN109776430B (zh) * | 2019-02-01 | 2022-05-13 | 福建农林大学 | 一种磺胺二甲嘧啶共晶及其制备方法 |
| GB201907591D0 (en) * | 2019-05-29 | 2019-07-10 | Eolas Res Limited | Composition and use |
| MX2021014774A (es) | 2019-06-04 | 2022-02-03 | Sunovion Pharmaceuticals Inc | Formulaciones de liberacion modificada y usos de las mismas. |
| CN110372575A (zh) * | 2019-07-10 | 2019-10-25 | 复旦大学 | 一种二氢吡啶钙拮抗剂共晶体及其制备方法和应用 |
| CN111053755B (zh) * | 2019-12-31 | 2022-03-29 | 金日制药（中国）有限公司 | 一种高渗透性的头孢克肟胶囊制剂制备方法 |
| WO2022162604A1 (ko) * | 2021-01-28 | 2022-08-04 | (주)아이엠디팜 | 카모스타트 및 니클로사마이드를 포함하는 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법 |
| CN113181179A (zh) * | 2021-04-08 | 2021-07-30 | 深圳市泰力生物医药有限公司 | 一种二氢吡啶类钙拮抗剂盐组合物及其制备方法和应用 |
| KR102544543B1 (ko) * | 2021-04-29 | 2023-06-16 | 대봉엘에스 주식회사 | L,d-엘도스테인의 개별적 공결정화물 |
| WO2024151838A1 (en) * | 2023-01-11 | 2024-07-18 | Board Of Regents, The University Of Texas System | Co-crystals with thin-film freeze-drying process to enhance delivery |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040220264A1 (en) * | 2003-03-17 | 2004-11-04 | Yu Ruey J | Bioavailability and improved delivery of acidic pharmaceutical drugs |
| CA2530193A1 (en) * | 2003-07-03 | 2005-01-20 | Teva Pharmaceutical Industries Ltd. | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| WO2010099255A1 (en) * | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
| EP2458996B1 (en) * | 2009-07-31 | 2016-09-07 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
| DK2459176T3 (en) * | 2009-07-31 | 2017-12-04 | Gruenenthal Gmbh | Crystallization process and bioavailability |
| DK2531200T3 (en) * | 2010-02-06 | 2017-09-11 | Gruenenthal Gmbh | COSTALLIZATION PROCEDURE AND BIOTA ACCESSIBILITY |
| KR20120105738A (ko) * | 2011-03-16 | 2012-09-26 | 현대약품 주식회사 | 장용코팅된 경구용 제제 |
| US8802658B2 (en) * | 2012-05-14 | 2014-08-12 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| EP3323418A1 (en) * | 2012-05-14 | 2018-05-23 | Antecip Bioventures II LLC | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions |
| US20140349974A1 (en) * | 2014-08-12 | 2014-11-27 | Antecip Bioventures Ii Llc | Zoledronic acid dosage forms for the treatment of pain |
| US20140348916A1 (en) * | 2014-08-11 | 2014-11-27 | Antecip Bioventures Ii Llc | Treatment of Pain with Oral Dosage Forms Comprising Zoledronic Acid and An Enhancer |
-
2016
- 2016-09-19 KR KR1020187010719A patent/KR20180053384A/ko not_active Withdrawn
- 2016-09-19 MX MX2018002627A patent/MX2018002627A/es unknown
- 2016-09-19 EP EP16847548.1A patent/EP3362071A4/en not_active Withdrawn
- 2016-09-19 JP JP2018514876A patent/JP2018527392A/ja active Pending
- 2016-09-19 AU AU2016324482A patent/AU2016324482A1/en not_active Abandoned
- 2016-09-19 WO PCT/US2016/052492 patent/WO2017049294A1/en not_active Ceased
- 2016-09-19 CN CN201680067559.3A patent/CN108601791A/zh active Pending
- 2016-09-19 CA CA2997378A patent/CA2997378A1/en not_active Abandoned
- 2016-09-19 PE PE2018000403A patent/PE20180931A1/es unknown
-
2018
- 2018-03-15 US US15/922,278 patent/US20190083407A1/en not_active Abandoned
- 2018-03-16 CL CL2018000705A patent/CL2018000705A1/es unknown
- 2018-04-04 CO CONC2018/0003558A patent/CO2018003558A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2018000705A1 (es) | 2018-08-24 |
| AU2016324482A1 (en) | 2018-03-29 |
| JP2018527392A (ja) | 2018-09-20 |
| CA2997378A1 (en) | 2017-03-23 |
| KR20180053384A (ko) | 2018-05-21 |
| PE20180931A1 (es) | 2018-06-08 |
| EP3362071A4 (en) | 2019-07-17 |
| CN108601791A (zh) | 2018-09-28 |
| EP3362071A1 (en) | 2018-08-22 |
| WO2017049294A1 (en) | 2017-03-23 |
| US20190083407A1 (en) | 2019-03-21 |
| MX2018002627A (es) | 2018-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018002627A (es) | Metodo de cristalizacion y biodisponibilidad. | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| ES2820879R1 (es) | Composiciones para la liberación controlada de ingredientes activos y métodos de preparación de las mismas | |
| IL275639A (en) | Formulation for RNA administration | |
| PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| AU2016219653A1 (en) | Crystallization Method and Bioavailability | |
| IL257371A (en) | Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient | |
| DK3727555T3 (da) | Oral delivery of active drug substances | |
| CO2017004714A2 (es) | Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina | |
| BR112017003219A2 (pt) | formulação de acetato de abiraterona e métodos de uso | |
| IL253619A0 (en) | Encapsulation of high potency active agents | |
| MA42991A (fr) | Stabilisation de compositions pharmaceutiques de camptothécine | |
| MX385925B (es) | Oritavancina de alta pureza y método para producir la misma. | |
| MX391152B (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas. | |
| JO3683B1 (ar) | صياغة صلبة عبر الفم تحتوي على إرينوتيكان وطريقة لتحضيرها | |
| MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
| ZA201806357B (en) | Protein based excipient for active pharmaceutical ingredients | |
| EP3093023A4 (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| EP3362048A4 (en) | COMPOSITION FOR INTRAORAL ADMINISTRATION OF PEPTIDES AND BIOLOGICALLY ACTIVE PROTEINS | |
| DK3168214T3 (da) | Substituerede 2-thioxo-imidazolidin-4-oner og spiro- analoger deraf, aktiv anti-canceringrediens, farmaceutisk sammensætning, medicinpræparat, fremgangsmåde til behandling af prostatacancer | |
| IL271596A (en) | Preparations for administering drugs and methods of using them | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| MX391186B (es) | Metodo para preparar un sistema de suministro de uno o mas ingredientes activos en una composicion comestible. | |
| IL252579B (en) | History of methyl-(1h-pyrazolo-4-yl-)-3-methyl-1h-pyrazolo[3,4-d]pyrimidine and pharmaceutical preparations containing them | |
| MX384254B (es) | Formulaciones para mejorar la eficacia de farmacos hidrofobicos. |